iRhythm Technologies Inc. (IRTC) saw its stock price surge 5.91% in after-hours trading on Thursday, following the release of its impressive third-quarter 2025 financial results that exceeded analyst expectations and prompted the company to raise its full-year guidance.

The digital healthcare company, known for its cardiac monitoring solutions, reported Q3 revenue of $192.9 million, significantly surpassing the IBES estimate of $184.7 million. This represents a robust 30.7% year-over-year growth compared to the same period in 2024. iRhythm's adjusted net loss narrowed to $0.06 per share, outperforming the analyst consensus estimate of a $0.31 loss per share.

iRhythm's strong performance was underpinned by several factors. The company achieved a gross margin of 71.1%, marking a 230-basis point improvement year-over-year. This expansion in profitability, coupled with the substantial revenue growth, signals the increasing efficiency and market penetration of iRhythm's innovative cardiac monitoring technologies. Furthermore, the company has raised its fiscal year 2025 revenue guidance to between $735 million and $740 million, reflecting management's confidence in sustained growth momentum. The positive results and outlook have clearly resonated with investors, as evidenced by the significant after-hours stock price movement.